Biogen

As Biogen's sales flatline, CEO Chris Viehbacher touts progress on Leqembi, Skyclarys and other launches
As Biogen's sales flatline, CEO Chris Viehbacher touts progress on Leqembi, Skyclarys and other launches
Fierce Pharma
Biogen
Pharma CEOs
Chris Viehbacher
earnings
Leqembi
Skyclarys
Flag link:
Biogen's M&A, Alzheimer's drug launch costs spark profit forecast cut
Biogen's M&A, Alzheimer's drug launch costs spark profit forecast cut
Reuters
Biogen
Alzheimer's disease
Leqembi
Reata
M&A
earnings
Flag link:
Biogen-Sage Therapeutics postpartum depression pill priced at $15,900
Biogen-Sage Therapeutics postpartum depression pill priced at $15,900
Reuters
Biogen
SAGE Therapeutics
postpartum depression
drug pricing
Zurzuvae
Flag link:
Eisai says new data could support more convenient form of Alzheimer’s drug Leqembi
Eisai says new data could support more convenient form of Alzheimer’s drug Leqembi
BioPharma Dive
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug
Reuters
Roche
legal
Biogen
biosimilars
Actemra
Flag link:
Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO
Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO
Stat
Biogen
Christopher Viehbacher
Pharma CEOs
risk
Flag link:
As 'harvest time' arrives for Alzheimer's, neuroscientist reflects on next steps for drug development
As 'harvest time' arrives for Alzheimer's, neuroscientist reflects on next steps for drug development
Fierce Biotech
Alzheimer's disease
Biogen
Eisai
Eli Lilly
Leqembi
donanemab
Flag link:
Biogen's Aduhelm headache returns as appeals court revives part of investor lawsuit
Biogen's Aduhelm headache returns as appeals court revives part of investor lawsuit
Fierce Pharma
Biogen
Aduhelm
legal
Eisai
Alzheimer's disease
Flag link:
6 Drugs Approved Despite Failed Trials or Minimal Data
6 Drugs Approved Despite Failed Trials or Minimal Data
BioSpace
Ipsen
Sohonos
Sarepta Therapeutics
Elevidys
Biogen
Qalsody
Eisai
Aduhelm
Jazz Pharma
PharmaMar
Zepzelca
Acadia Pharma
Nuplazid
Flag link:
Biogen nabs FDA nod for biosimilar version of Roche's blockbuster Actemra
Biogen nabs FDA nod for biosimilar version of Roche's blockbuster Actemra
Fierce Pharma
Biogen
Roche
Actemra
autoimmune disease
biosimilars
Flag link:
Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen
Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen
Reuters
Biogen
Eisai
Japan
Leqembi
Alzheimer's disease
Flag link:
The Alzheimer’s Treatment Landscape: Leqembi vs. Donanemab
The Alzheimer’s Treatment Landscape: Leqembi vs. Donanemab
BioSpace
Alzheimer's disease
Eli Lilly
Biogen
Eisai
Leqembi
donanemab
Flag link:
Sage lays off 40%, shakes up C-suite to squeeze a profit out of partially rejected zuranolone
Sage lays off 40%, shakes up C-suite to squeeze a profit out of partially rejected zuranolone
Fierce Biotech
SAGE Therapeutics
layoffs
Biogen
major depressive disorcer
zuranolone
Flag link:
FDA Decisions 2023: Sandoz, Gilead Sciences and More
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Flag link:
FDA Approves Sandoz Biosimilar to Biogen’s MS Therapy Tysabri
FDA Approves Sandoz Biosimilar to Biogen’s MS Therapy Tysabri
BioSpace
Biogen
Sandoz
FDA
biosimilars
MS
multiple sclerosis
Tysabri
Flag link:
Brii Biosciences aims to come up big where Sage and Biogen fell short
Brii Biosciences aims to come up big where Sage and Biogen fell short
Pharma Voice
Brii Biosciences
depression
SAGE Therapeutics
Biogen
BRII-296
postpartum depression
Flag link:
Biogen kicks off 1,000 layoffs as part of CEO Viehbacher’s ‘complete redesign’
Biogen kicks off 1,000 layoffs as part of CEO Viehbacher’s ‘complete redesign’
Fierce Pharma
Biogen
layoffs
restructuring
Flag link:
How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B
How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B
Fierce Pharma
Biogen
Reata Pharmaceuticals
M&A
Skyclarys
Friedreich’s ataxia
Flag link:
New Alzheimer’s drug raises hopes — along with questions
New Alzheimer’s drug raises hopes — along with questions
Medical Marketing and Media
FDA
Alzheimer's disease
Eisai
Biogen
Leqembi
Flag link:
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
Flag link:

Pages